Sio Capital Management, LLC Precision Biosciences Inc Transaction History

Sio Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.15 - $3.34 $1.16 Million - $3.37 Million	1,008,993 New	1,008,993 $1.61 Million
Q1 2022 May 16, 2022	SELL	$2.96 - $7.76 $761,214 - $2 Million	-257,167 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$9.18 - $14.15 $332,986 - $513,262	-36,273 Reduced 12.36%	257,167 $2.97 Million
Q2 2021 Aug 16, 2021	SELL	$8.07 - $12.52 $289,947 - $449,831	-35,929 Reduced 10.91%	293,440 $3.67 Million
Q1 2021 May 14, 2021	BUY	$8.57 - $15.79 $100,483 - $185,137	11,725 Added 3.69%	329,369 $3.41 Million
Q4 2020 Feb 16, 2021	SELL	$5.98 - $12.47 $229,147 - $477,837	-38,319 Reduced 10.76%	317,644 $2.65 Million
Q3 2020 Nov 16, 2020	BUY	$4.65 - $8.73 $794,731 - $1.49 Million	170,910 Added 92.36%	355,963 $2.19 Million
Q2 2020 Aug 14, 2020	BUY	$4.66 - $8.7 $862,346 - $1.61 Million	185,053 New	185,053 $1.54 Million
Q1 2020 May 15, 2020	SELL	$5.05 - $15.01 $219,336 - $651,929	-43,433 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$6.32 - $19.66 $274,496 - $853,892	43,433 New	43,433 $603,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $539M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Sio Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sio Capital Management, LLC with notifications on news.